Patents by Inventor Aurelia Conte
Aurelia Conte has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240132522Abstract: The present disclosure relates to compounds of Formula (I): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for modulating PARP1 activity and may be used in the treatment of disorders in which PARP1 activity is implicated, such as cancer.Type: ApplicationFiled: August 29, 2023Publication date: April 25, 2024Inventors: Jayakanth KANKANALA, Jeremy D. PETTIGREW, Aurelia CONTE, Jiyun CHEN, Son Minh PHAM
-
Patent number: 9809599Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6 and n are as described herein, compositions including the compounds and methods of using the compounds. The present compounds are useful as fatty-acid binding protein (FABP) 4 and/or 5 inhibitors and may be used for the treatment or prophylaxis of lipodystrophy, type 2 diabetes, dyslipidemia, atherosclerosis, liver diseases involving inflammation, steatosis and/or fibrosis, such as non-alcoholic fatty liver disease, in particular non-alcoholic steatohepatitis, metabolic syndrome, obesity, chronic inflammatory and autoimmune inflammatory diseases.Type: GrantFiled: November 11, 2015Date of Patent: November 7, 2017Assignee: Hoffmann-La Roche Inc.Inventors: Simona M. Ceccarelli, Aurelia Conte, Holger Kuehne, Bernd Kuhn, Werner Neidhart, Ulrike Obst Sander, Markus Rudolph
-
Patent number: 9708340Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, W, A and B are as described herein, compositions including the compounds and methods of using the compounds.Type: GrantFiled: September 16, 2015Date of Patent: July 18, 2017Assignee: Hoffmann-La Roche Inc.Inventors: Bernd Buettelmann, Simona M. Ceccarelli, Aurelia Conte, Holger Kuehne, Bernd Kuhn, Werner Neidhart, Ulrike Obst Sander, Hans Richter
-
Patent number: 9562052Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, A1, A2, A3, m, n and p are as described herein, compositions including the compounds and methods of using the compounds.Type: GrantFiled: February 20, 2015Date of Patent: February 7, 2017Assignee: Hoffmann-La Roche Inc.Inventors: Bernd Buettelmann, Aurelia Conte, Holger Kuehne, Bernd Kuhn, Werner Neidhart, Ulrike Obst Sander, Hans Richter
-
Publication number: 20160185795Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, W, A and B are as described herein, compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: September 16, 2015Publication date: June 30, 2016Applicant: HOFFMANN-LA ROCHE INC.Inventors: BERND BUETTELMANN, SIMONA M. CECCARELLI, AURELIA CONTE, HOLGER KUEHNE, BERND KUHN, WERNER NEIDHART, ULRIKE OBST SANDER, HANS RICHTER
-
Patent number: 9278918Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, W, A and B are as described herein, compositions including the compounds and methods of using the compounds.Type: GrantFiled: September 17, 2015Date of Patent: March 8, 2016Assignee: Hoffmann-La Roche Inc.Inventors: Bernd Buettelmann, Simona M. Ceccarelli, Aurelia Conte, Holger Kuehne, Bernd Kuhn, Werner Neidhart, Ulrike Obst Sander, Hans Richter
-
Publication number: 20160060270Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6 and n are as described herein, compositions including the compounds and methods of using the compounds. The present compounds are useful as fatty-acid binding protein (FABP) 4 and/or 5 inhibitors and may be used for the treatment or prophylaxis of lipodystrophy, type 2 diabetes, dyslipidemia, atherosclerosis, liver diseases involving inflammation, steatosis and/or fibrosis, such as non-alcoholic fatty liver disease, in particular non-alcoholic steatohepatitis, metabolic syndrome, obesity, chronic inflammatory and autoimmune inflammatory diseases.Type: ApplicationFiled: November 11, 2015Publication date: March 3, 2016Inventors: Simona M. Ceccarelli, Aurelia Conte, Holger Kuehne, Bernd Kuhn, Werner Neidhart, Ulrike Obst Sander, Markus Rudolph
-
Publication number: 20160002152Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, W, A and B are as described herein, compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: September 17, 2015Publication date: January 7, 2016Applicant: HOFFMANN-LA ROCHE INC.Inventors: BERND BUETTELMANN, SIMONA M. CECCARELLI, AURELIA CONTE, HOLGER KUEHNE, BERND KUHN, WERNER NEIDHART, ULRIKE OBST SANDER, HANS RICHTER
-
Publication number: 20150368256Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, A1, A2, A3, m, n and p are as described herein, compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: February 20, 2015Publication date: December 24, 2015Applicant: HOFFMANN-LA ROCHE INC.Inventors: Bernd Buettelmann, Aurelia Conte, Holger Kuehne, Bernd Kuhn, Werner Neidhart, Ulrike Obst Sander, Hans Richter
-
Patent number: 9199938Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6 and n are as described herein, compositions including the compounds and methods of using the compounds. The present compounds are useful as fatty-acid binding protein (FABP) 4 and/or 5 inhibitors and may be used for the treatment or prophylaxis of lipodystrophy, type 2 diabetes, dyslipidemia, atherosclerosis, liver diseases involving inflammation, steatosis and/or fibrosis, such as non-alcoholic fatty liver disease, in particular non-alcoholic steatohepatitis, metabolic syndrome, obesity, chronic inflammatory and autoimmune inflammatory diseases.Type: GrantFiled: November 1, 2012Date of Patent: December 1, 2015Assignee: HOFFMANN-LA ROCHE INC.Inventors: Simona M. Ceccarelli, Aurelia Conte, Holger Kuehne, Bernd Kuhn, Werner Neidhart, Ulrike Obst Sander, Markus Rudolph
-
Publication number: 20150148363Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2 and n are as described herein, compositions including the compounds and methods of using the compounds. The compounds are useful as inhibitors of hormone sensitive lipase (HSL) for the treatment of diabetes, metabolic syndrome and obesity.Type: ApplicationFiled: January 30, 2015Publication date: May 28, 2015Inventors: Jean Ackermann, Aurelia Conte, Daniel Hunziker, Werner Neidhart, Matthias Nettekoven, Tanja Schulz-Gasch, Stanley Wertheimer
-
Publication number: 20140005400Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2 and n are as described herein, compositions including the compounds and methods of using the compounds. The compounds are useful as inhibitors of hormone sensitive lipase (HSL) for the treatment of diabetes, metabolic syndrome and obesity.Type: ApplicationFiled: August 29, 2013Publication date: January 2, 2014Applicant: Hoffmann-La Roche Inc.Inventors: Jean Ackermann, Aurelia Conte, Daniel Hunziker, Werner Neidhart, Matthias Nettekoven, Tanja Schulz-Gasch, Stanley Wertheimer
-
Patent number: 8552024Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2 and n are as described herein, compositions including the compounds and methods of using the compounds. The compounds are useful as inhibitors of hormone sensitive lipase (HSL) for the treatment of diabetes, metabolic syndrome and obesity.Type: GrantFiled: August 8, 2011Date of Patent: October 8, 2013Assignee: Hoffman-La Roche Inc.Inventors: Jean Ackermann, Aurelia Conte, Daniel Hunziker
-
Patent number: 8501768Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, A, E, G and n are as described herein, compositions including the compounds and methods of using the compounds. The compounds are useful as inhibitors of hormone sensitive lipase (HSL) and may be used for the treatment of diabetes, metabolic syndrome, dyslipidemia, atherosclerosis, obesity, cardiovascular diseases, myocardial dysfunction, inflammation, non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.Type: GrantFiled: May 4, 2012Date of Patent: August 6, 2013Assignee: Hoffmann-La Roche Inc.Inventors: Aurelia Conte, Daniel Hunziker, Werner Neidhart, Matthias Nettekoven, Tanja Schulz-Gasch
-
Patent number: 8497288Abstract: The invention provides novel compounds having the general formula (I), wherein R1, R2, R3 and A are as described herein, compositions including the compounds and methods of using the compounds. These compounds are useful as inhibitors of hormone sensitive lipase (HSL) and may be used in the treatment of diabetes, metabolic syndrome, dyslipidemia, atherosclerosis, obesity, cardiovascular diseases, myocardial dysfunction, inflammation, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.Type: GrantFiled: May 2, 2012Date of Patent: July 30, 2013Assignee: Hoffmann-La Roche Inc.Inventors: Aurelia Conte, Daniel Hunziker, Werner Neidhart, Matthias Nettekoven, Tanja Schulz-Gasch
-
Patent number: 8470843Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3 and A are as described herein, compositions including the compounds and methods of using the compounds.Type: GrantFiled: July 12, 2011Date of Patent: June 25, 2013Assignee: Hoffmann-La Roche Inc.Inventors: Jean Ackermann, Aurelia Conte, Daniel Hunziker, Werner Neidhart, Matthias Nettekoven, Tanja Schulz-Gasch, Stanley Wertheimer
-
Patent number: 8440710Abstract: The present invention relates to compounds of formula (I) as well as pharmaceutically acceptable salts thereof. The are useful as HSL inhibitors and may, for example, be used in treatment of diabetes, metabolic syndrome, dyslipidemia, atherosclerosis, and obesity.Type: GrantFiled: October 8, 2010Date of Patent: May 14, 2013Assignee: Hoffmann-La Roche Inc.Inventors: Jean Ackermann, Stephan Brugger, Aurelia Conte, Daniel Hunziker, Werner Neidhart, Matthias Nettekoven, Tanja Schulz-Gasch, Stanley Wertheimer
-
Patent number: 8399676Abstract: Compounds of formula (I) as well as pharmaceutically acceptable salts thereof can be used in the form of pharmaceutical compositions, wherein A1, A2, R1, R2, R3 and R4 have the significance given in claim 1.Type: GrantFiled: July 23, 2010Date of Patent: March 19, 2013Assignee: Hoffman-La Roche Inc.Inventors: Jean Ackermann, Aurelia Conte, Daniel Hunziker, Werner Neidhart, Matthias Nettekoven, Stanley Wertheimer
-
Patent number: 8389539Abstract: Compounds of formula (I) as well as pharmaceutically acceptable salts thereof can be used in the form of pharmaceutical compositions, wherein R1, R2, R3 and n have the significance given in claim 1.Type: GrantFiled: November 22, 2010Date of Patent: March 5, 2013Assignee: Hoffman-La Roche Inc.Inventors: Jean Ackermann, Aurelia Conte, Daniel Hunziker, Werner Neidhart, Matthias Nettekoven, Tanja Schulz-Gasch, Stanley Wertheimer
-
Patent number: 8329904Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein n, m, A, R1 and R2 have the significance given in the description. The compounds are useful as HSL inhibitors and may be used in the treatment or prophylaxis of diabetes, dyslipidemia, atherosclerosis or obesity.Type: GrantFiled: May 3, 2010Date of Patent: December 11, 2012Assignee: Hoffmann-La Roche Inc.Inventors: Jean Ackermann, Aurelia Conte, Daniel Hunziker, Werner Neidhart, Matthias Nettekoven, Tanja Schulz-Gasch, Stanley Wertheimer